Join the Oncology Voice Network. Join for Free
Interim Impact The Rise of Fractional Medical Affairs Roles in Pharmas New Reality
fractional medical affairs roles interim positions gig economy in pharma pharmaceutical staffing trends fractional work benefits

Interim Impact The Rise of Fractional Medical Affairs Roles in Pharmas New Reality


Share This Article


Summary

In this episode, Tom Caravela and Daniel Snyder explore the rise of fractional medical affairs roles in the post-COVID era. They define interim and fractional positions, highlighting how they benefit both job seekers and companies. The discussion covers the increase in these roles, company utilization of interim talent, disadvantages, and compensation expectations, offering negotiation tips for candidates. They also discuss the future of fractional staffing, market trends, and the gig economy's impact on pharma and biotech. The episode ends with cost-effective strategies and gratitude to the audience.

Key Points

  • Fractional medical affairs roles offer a cost-effective solution for pharmaceutical companies to address specific project needs without committing to full-time hires. The rise in fractional positions is driven by economic uncertainties and the need for companies to streamline operations while still advancing critical projects. Engaging in fractional work can help professionals bridge employment gaps, expand their networks, and gain new therapeutic experience, making them more attractive in the job market.

Click for Source
fractional medical affairs roles, interim positions, gig economy in pharma, pharmaceutical staffing trends, fractional work benefits

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Explore OVN